Medical Therapy for Acute Myocardial Infarction: Where Do We Go from Here?

1. National Heart, Lung, and Blood Institute. Morbidity and mortality: chartbook on cardiovascular, lung and blood diseases. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1992 Jan

2. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993;342:759–766

3. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311–322

4. The Thrombolysis in Myocardial Infarction (TIMI) Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618–627

5. Braunwald E . Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation 1989;79:441–144

6. Califf RM Topol EJ Gersh BJ . From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy, J Am Coll Cardiol 1989;14:1382–1388

7. Timm TC Ross R Mckendall GR . Left ventricular function and early cardiac events as a function of time to treatment with t-PA: a report from TIMI II (abstract). Circulation 1991;84 (suppl 2):II–230

8. Weaver WD Cerqueira M Hallstrom AP . Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA 1993;270:1211–1216

9. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–1622

10. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682

11. Ho MT Eisenberg MS Litwin PE . Delay between onset of chest pain and seeking medical care: the effect of public education. Ann Emerg Med 1989;18:727–731

12. Leitch JW Birbara T Freedman B . Factors influencing the time from onset of chest pain to arrival at hospital. Med J Aust 1989;150:6–10

13. Wielgosz ATJ Nolan RP Earp JA . Reasons for patients’ delay in response to symptoms of acute myocardial infarction. Can Med Assoc J 1988;139:853–857

14. Kline EM Smith DD Martin JS . In-hospital treatment delays in patients treated with thrombolytic therapy: a report of the GUSTO Time to Treatment Substudy (abstract). Circulation 1992;86 (suppl 1):I–702

15. Gonzalez ER Jones LA *** Ornato JP . Hospital delays and problems with thrombolytic administration in patients receiving thrombolytic therapy: a multicenter prospective assessment. Ann Emerg Med 1992;21:1215–1221

National Institutes of Health. National Heart Attack Alert Program. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. NTH Publication No.93-3278, September 1993

17. American Heart Association/Emergency Cardiac Care Committee and Subcommittees. Guidelines for cardiopulmonary resuscitation and emergency cardiac care, III: adult advanced cardiac life support. JAMA 1992;268:2199–2241

18. Purvis J . Novel and innovative dosing regimens in thrombolytic therapy for acute myocardial infarction. J Thromb Thrombolysis 1995 (in press)

19. Becker RC . Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians. Am Heart J 1992;124:183–193

20. Becker RC Cannon CP . Hirudin: its biology and clinical use. J Thromb Thrombolysis 1994;1:7–16

21. Cannon CP Mccabe CH Henry TD . A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tPA and aspirin for acute myocardial infarction: the results of TIMI 5. J Am Coll Cardiol 1994;23:993–1003

22. Becker RC . Toward establishing comprehensive universal guidelines for antithrombotic therapy. J Thromb Thrombolysis 1995 (in press)

23. Becker RC . The importance of clinical trials in developing safe and effective treatments for acute myocardial infarction: from TIMI II to TIMI 9 and GUSTO II. J Thromb Thrombolysis 1995 (in press)

24. Grines CL Browne KF Marco J . A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673–679

25. Zijlstra F De Boer MJ Hoorntje JCA . A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680–684

26. De Boer MJ Hoorntje JCA Ottervanger JP . Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. J Am Coll Cardiol 1994;23:1004–1008

27. O'Keefe JH Bailey WL Rutherford BD Hartzler GO . Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients: results in an unselected population and high-risk subgroups. Am J Cardiol 1993;72:107G–115G

28. Ellis SG Da Silva ER Heyndrickx GR (for the RESCUE Investigators). Final results of the randomized RESCUE study evaluating PTCA after failed thrombolysis for patients with anterior infarction (abstract). Circulation 1993;88(suppl): 1–106

29. The CORAMI Study Group. Outcome of attempted rescue coronary angioplasty after failed thrombolysis for acute myocardial infarction. Am J Cardiol 1995 (in press)

30. Ohman EM George BS White CJ . Use of aortic counter pulsation to improve sustained coronary artery patency during acute myocardial infarction: results of a randomized trial. Circulation 1994;90:792–799

31. Jafri W Borzak S . Medical therapy of acute myocardial infarction. J Intensive Care Med 1995;10:54–63